LLY
Eli Lilly and Company
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Eli Lilly and Company.
Coverage
HIMS Perfect Storm: FDA, DOJ, and Novo Nordisk Close In — Stock Down 75% From Highs
Hims & Hers faces a triple regulatory and legal assault. FDA crackdown, DOJ criminal referral, and now a Novo Nordisk patent lawsuit have cratered the stock from $68 to $17 in weeks. We break down the compounding threats.
Hims Launches $99 GLP-1 Pill, Undercuts Novo Nordisk by 90%
Hims debuts compounded oral semaglutide at $49-99/month vs $936+ for branded. But without Novo's patented SNAC absorption tech, critics call it a 'waste of $49.' The science and market implications.
Earnings release dates
| Quarter | End date | Publication date | Release |
|---|---|---|---|
| 2026 Q2 | 2026-06-30 | 2026-08-06 | Details → |
| 2026 Q1 | 2026-03-31 | 2026-04-30 | Details → |
| 2025 Q4 | 2025-12-31 | 2026-02-04 | Details → |
| 2025 Q3 | 2025-09-30 | 2025-10-30 | Details → |
| 2025 Q2 | 2025-06-30 | 2025-08-07 | Details → |
| 2025 Q1 | 2025-03-31 | 2025-05-01 | Details → |
| 2024 Q4 | 2024-12-31 | 2025-02-06 | Details → |
| 2024 Q3 | 2024-09-30 | 2024-10-30 | Details → |
| 2024 Q2 | 2024-06-30 | 2024-08-08 | Details → |
| 2024 Q1 | 2024-03-31 | 2024-04-30 | Details → |
Company History
Colonel Eli Lilly establishes the firm in Indianapolis, focusing on quality pharmaceuticals; sets foundation for long-term growth, going public in 1952.
Partners with University of Toronto to produce insulin, saving lives from diabetes; establishes Lilly as a diabetes leader.
Among first to scale penicillin during WWII, marking entry into antibiotics; boosted post-war sales and positioned Lilly as global manufacturing powerhouse.
First human-health product via DNA tech; shifted narrative from animal-sourced drugs, enhancing safety and sparking biotech era.
Blockbuster SSRI antidepressant becomes cultural icon; generated billions, but patent expiry in 2001 forced diversification.
Gained full control via ICOS buyout; long-duration ED drug competed with Viagra, adding steady revenue stream.
Tirzepatide's dual GLP-1/GIP action revolutionizes treatment; sparked obesity drug boom, with sales exploding and stock tripling by 2025.
First pharma firm to hit $1T valuation, fueled by GLP-1 dominance; narrative shifts to 'weight-loss giant' amid pipeline bets in Alzheimer's and gene therapy.
